HomeADVM • NASDAQ
add
Adverum Biotechnologies Inc
Previous close
$7.86
Day range
$7.70 - $8.19
Year range
$7.40 - $29.70
Market cap
163.98M USD
Avg Volume
397.16K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 26.84M | 110.01% |
Net income | -24.79M | 14.69% |
Net profit margin | — | — |
Earnings per share | -1.50 | 48.28% |
EBITDA | -25.84M | 9.79% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 193.33M | 17.68% |
Total assets | 267.83M | -2.81% |
Total liabilities | 85.54M | -27.40% |
Total equity | 182.29M | — |
Shares outstanding | 16.48M | — |
Price to book | 0.71 | — |
Return on assets | -30.44% | — |
Return on capital | -32.31% | — |
Cash Flow
Net change in cash
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Net income | -24.79M | 14.69% |
Cash from operations | -23.24M | -3.72% |
Cash from investing | -22.03M | -202.29% |
Cash from financing | 119.88M | — |
Net change in cash | 74.61M | 8,587.83% |
Free cash flow | -18.87M | -68.34% |
About
Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration. Wikipedia
Founded
Jan 1, 2006
Headquarters
Website
Employees
121